Monoamine Oxidase B Inhibitors in Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease: A Review of Symptomatic and Potential Disease-Modifying Effects

By Schapira Anthony H.V.  

CNS Drugs, Vol. 25, Iss. 12, 2011-12 ,pp. : 1061-1071

Adis International

Access to resources Recommend Favorite

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

By Kaakkola S.  

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Tobacco Leaf, Smoke and Smoking, MAO Inhibitors, Parkinson's Disease and Neuroprotection; Are There Links?

By Castagnoli K.   Murugesan T.  

Neurotoxicology, Vol. 25, Iss. 1, 2004-01 ,pp. : 279-291

Elsevier

Access to resources Recommend Favorite